Nuclera–Bertelsen J: management, 202403– Chief Commercial Officer before Institute for Protein Innovation + Diagenode + Abcam

	Period	2024-03-14
	Organisation	Nuclera Ltd.
	Group	Nuclera (Group)
	Product	eProtein Discovery™ benchtop system
	Product 2	BIOTECH
	Person	Bertelsen, Jospeh (Joe) (Nuclera 202403– Chief Commercial Officer before Institute for Protein Innovation + Diagenode)

Nuclera Ltd.. (3/14/24). "Press Release: Nuclera Appoints Joseph Bertelsen as Chief Commercial Officer". Cambridge.

Key appointment to lead global commercial launch of eProtein Discovery platform

Nuclera, the biotechnology company enabling rapid protein expression and purification screening through its benchtop protein platform, today announced the appointment of Joseph Bertelsen as Chief Commercial Officer (CCO). With over 20 years’ commercial leadership experience in the life science tools and drug development industries, Joseph brings an extensive sales record that will be instrumental to the commercial launch strategy and explosive adoption of Nuclera’s eProtein Discovery™ platform.

Joseph joins Nuclera from the Institute for Protein Innovation, a research institute focused on providing synthetic antibodies and protein expertise, where he was the Director of Commercialization responsible for establishing a sustainable antibody distribution entity. Joseph has held numerous senior positions at protein-focused companies driving strategies to maximize industry impact and profitability. Prior roles include SVP of Global Sales and Marketing at Diagenode (acquired by Hologic), a life sciences company providing tools for molecular epigenetics research and infectious disease diagnostics, and Director of Sales at Abcam, a company specializing in the production and distribution of research antibodies. Joseph has a MSc in Pharmaceutical Medicine from Hibernia College, Ireland, and a BSc in Chemical Engineering from Michigan State University.

Joseph Bertelsen, Chief Commercial Officer: “Nuclera is disrupting the protein market with their technology allowing researchers to more easily and quickly have access to proteins for their research. Their benchtop technology has the potential to greatly reduce costs and timelines associated with the drug discovery process. I’m excited to be joining the team at such an exciting phase of the journey to drive adoption of Nuclera’s eProtein Discovery.”

Dr Michael Chen, CEO and co-founder, Nuclera, said: “Appointing our first Chief Commercial Officer marks an exciting step in Nuclera’s journey. With Joe’s strong track record and experience in achieving revenue growth, I look forward to partnering with him on rapidly increasing the number of protein makers that use our eProtein Discovery system to make proteins accessible.”

For more information about Nuclera’s eProtein Discovery platform, please visit: https://www.nuclera.com/system/

ENDS

Media contact:

Dr Ben Rutter
Zyme Communications
Tel: +44(0)7920 770 935
Email: ben.rutter@zymecommunications.com

About Nuclera www.nuclera.com

Nuclera’s mission is to better human health by enabling scientists to easily access the proteins they need for drug discovery research. The Company’s eProtein Discovery™ benchtop system accelerates protein expression and purification workflows within research labs.

The platform reduces the timelines and costs associated with protein expression and purification through automated construct screening to inform protein scale-up resulting in mg amounts in less than 48 hours. Integrating digital microfluidics, protein quality assays, and cell-free protein synthesis on smart cartridges, eProtein Discovery enables rapid access to even challenging proteins at high quality.

Founded in 2013, Nuclera’s offices are located in Cambridge (UK) and Boston (US).

For more information please visit: www.nuclera.com